Featured series 
Tag: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
-
Nation & World
Gene therapy was a ‘last shot’
Three years after undergoing gene therapy at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to treat a life-threatening immune disorder, an Ohio college student is no longer thinking about his own “last shot” for health, but rather about medical school and “giving back.”
-
Nation & World
How a child made scientists think of cytokines as knobs instead of switches
A rare anemia is opening scientists up to a new way of thinking about how to adapt and employ cytokines, messenger molecules of the blood and immune system, as tools for treatment and the promise of precision medicine.
-
Nation & World
New hope for children with brain tumors
A new study out of Harvard-affiliated Dana-Farber/Boston Children’s Cancer and Blood Disorders Center suggests that precision medicine can provide vital care in treatment and diagnosis of pediatric brain tumors.
-
Nation & World
New approach to cancer treatment carries success with caveat
Restoring the cancer-killing zeal of T cells is being seen as one of the most successful new approaches to cancer treatment in nearly a decade, although researchers note it has shown effectiveness in only about a quarter of cases.
-
Nation & World
Gene therapy for sickle cell disease passes key preclinical test
A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red-cell damage in mice with sickle cell disease, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported in the Journal of Clinical Investigation.
-
Nation & World
High poverty’s effect on childhood leukemia
Children with acute lymphoblastic leukemia who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, according to a new study.
-
Nation & World
Red blood cell production increases, but cost goes down
New research suggests a way to cost-effectively manufacture red blood cells from stem cells; the patients who could potentially benefit include those who cannot use blood currently available in blood banks.
-
Nation & World
‘Achilles’ heel’ of sickle cell disease?
Gene-editing study reveals pathway that could help short circuit sickle cell disease.
-
Nation & World
‘Bubble boy’ gene therapy raises hope
A new form of gene therapy for boys with the life-threatening condition known as “bubble boy” disease appears to be both effective and safe, according to an international clinical trial run by a team from Harvard Medical School, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and other institutions.
-
Nation & World
New hope for ‘bubble boy’ disease
Children born with so-called “bubble boy” disease have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years of outcome data by researchers at the Harvard-affiliated Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
